Vimarsana
Biggest News Aggregation in the World

Page 33 - Guy Goodwin News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Guy Goodwin. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Guy Goodwin Today - Breaking & Trending Today

First ever human trial confirms magic mushrooms are safe to treat mental health patients - Vimarsana News

First ever human trial confirms magic mushrooms are safe to treat mental health patients

The psychedelic chemical produced in the fungi can be given in small doses to patients with depression and PTSD

Active ingredient in magic mushrooms could help treat mental health disorders including PTSD - Vimarsana News

Active ingredient in magic mushrooms could help treat mental health disorders including PTSD

Researchers in a study led by King's College London, found that psilocybin can be given safely in doses of either 10mg or 25mg to up to six patients. The trial is the first step in proving its effectiveness.

FinancialNewsMedia.com: North American Psychedelic Drugs Market Expected To Reach A Value Of $3.184 Billion In 2026 - Vimarsana News

FinancialNewsMedia.com: North American Psychedelic Drugs Market Expected To Reach A Value Of $3.184 Billion In 2026

PALM BEACH, Fla., Dec. 14, 2021 /PRNewswire/ -- FinancialNewsMedia.com News Commentary - The prevalence of mental health disorders has risen exponentially, and the development of novel medications

Investegate |COMPASS Pathways Announcements | COMPASS Pathways: COMPASS Pathways announces further positive results from groundbreaking phase IIb trial of investigational COMP360 psilocybin therapy for treatment-resistant depression - Vimarsana News

Investegate |COMPASS Pathways Announcements | COMPASS Pathways: COMPASS Pathways announces further positive results from groundbreaking phase IIb trial of investigational COMP360 psilocybin therapy for treatment-resistant depression

Investegate announcements from COMPASS Pathways, COMPASS Pathways announces further positive results from groundbreaking phase IIb trial of investigational COMP360 psilocybin therapy for treatment-resistant depression

COMPASS Pathways announces further positive results from groundbreaking phase IIb trial of investigational COMP360 psilocybin therapy for treatment-resistant depression - Vimarsana News

COMPASS Pathways announces further positive results from groundbreaking phase IIb trial of investigational COMP360 psilocybin therapy for treatment-resistant depression

- Positive topline results validated by additional analyses - Patient improvements beyond reduction of depression symptoms - Further insights into timing and circumstance of adverse events demonstrate